Overblog Alle Blogs
Edit post Folge diesem Blog Administration + Create my blog
MENU

Mein Blog umfasst die aktuellesten News, Forschungsleistung, neuesten Produkte und Service von Sino Biological Inc. und die aktuelle News von Life Sciences. Sie können sich hier wissenschaftlich informieren.Willkommen zu meinem Blog.Viel Spaß!

Werbung

IFNAR2 Antikörper ( FITC )

Sino Biological Inc. liefert IFNAR2 Antikörper ( FITC ) mit höherer Qualität und günstiger Kosten im Vergleich mit anderen globalen Lieferanten.

Weitere Informationen über IFNAR2 Antikörper ( FITC ) lesen Sie bitte: http://www.sinobiological.com/IFNAR2-Antibody-g-10067.html

Produkt-Information von IFNAR2 Antikörper

Immunogen

Recombinant Human IFNAR2 protein (Catalog#10359-H08H)

Reagents FITC-conjugated mouse monoclonal antibody

Clone ID

07

Ig Type

Mouse IgG1

Concentration

5 μl/Test, 0.2 mg/ml

Formulation Aqueous solution containing 0.5% BSA and 0.1% sodium azide
Preparation

This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IFNAR2 (rh IFNAR2; Catalog#10359-H08H; NP_997468.1; Met 1-Lys 243) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.

Usage Guide von IFNAR2 Antikörper

Specificity

Human IFNAR2

Flow Cytometry
IFNAR2 Flow Cytometry

Profile of anti-IFNAR2 reactivity on Jurkat cells (Left panel) and KG-1 cells (Right panel) analyzed by flow cytometry.

Flow cytometry was performed on a BD FACSCalibur flow cytometry system

Please refer to www.sinobiological.com/Flow-Cytometry-FACS-Protocols-a-750.html for technical protocols.

Storage This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.

Verwandte Produkte & Themen von IFNAR2 Antikörper

Related Areas:

Cancer>>Angiogenesis>>Cytokines/Chemokines in Angiogenesis>>IFNAR2

Immunology>>Cytokine & Receptor>>Interleukin & Receptor>>IL-10/Interferon Family>>IFNAR2

Proteins:
Molecule Species Description //For Detailed Info. and Price------CLICK! Cat. No
IFNAR2 Human IFNAR2/Fc Protein, Recombinant 10359-H02H
IFNAR2 Human IFNAR2 Protein, Recombinant 10359-H08H
Antibodies:
Molecule Application Description //For Detailed Info. and Price------CLICK! Cat. No
Human
IFNAR2
WB, ELISA IFNAR2 Antibody, Rabbit PAb 10359-RP01
Human
IFNAR2
WB, ELISA IFNAR2 Antibody, Rabbit PAb (Antigen Affinity Purified) 10359-RP02
Human
IFNAR2
WB, ELISA IFNAR2 Antibody, Mouse MAb 10359-MM07
Human
IFNAR2
FCM IFNAR2 Antibody ( FITC ) 10359-MM07-F

Hintergrund von IFNAR2 Antikörper

Interferon alpha/beta receptor 2, also known as IFN-alpha/beta receptor 2, Type I interferon receptor 2, IFNAR2 and IFNABR, is a single-pass type I membrane protein which belongs to thetype II cytokine receptor family. IFNAR2 is a receptor for interferons alpha and beta. IFNAR2 was detected in most lymphocytes, monocytes, and granulocytes, although IFNAR2 expression was higher in the monocytes and granulocytes than in the lymphocytes. The intra- and interdaily variations of IFNAR2 in lymphocytes, monocytes, and granulocytes were small. Among the lymphocyte subsets, IFNAR2 showed high expression in natural killer (NK) cells and low expression in T lymphocytes. Isoform 1 and isoform 3 of IFNAR2 are directly involved in signal transduction due to their interaction with the TYR kinase, JAK1. Isoform 1 also interacts with the transcriptional factors, STAT1 and STAT2. Both forms are potent inhibitors of type I IFN activity. Defects in IFNAR2 are associated with susceptibility to hepatitis B virus infection (HBV infection). Approximately one third of all cases of cirrhosis and half of all cases of hepatocellular carcinoma can be attributed to chronic HBV infection. HBV infection may result in subclinical or asymptomatic infection, acute self-limited hepatitis, or fulminant hepatitis requiring liver transplantation.

References

  1. Novick D. et al.,1995, J. Leukoc. Biol. 57: 712-18.
  2. Chill JH. et al., 2003, Structure 11: 791-802.
  3. Tochizawa,S. et al.,2004, J Pharmacol Toxicol Methods. 50 (1): 59-66.
  4. Frodsham A.J. et al., 2006, Proc. Natl. Acad. Sci. USA. 103: 9148-53.

Primary Antibody Products

Werbung
Zurück zu Home
Diesen Post teilen
Repost0
Um über die neuesten Artikel informiert zu werden, abonnieren:
Kommentiere diesen Post